Shanghai Pioneer Holding Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Shanghai Pioneer Holding için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi	22.1%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price

Jul 15

Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024

Apr 24

Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024

Apr 03

Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 01

Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks

Mar 22

Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital

Feb 26

Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?

Oct 21

Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024

Sep 18

Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024

Sep 01

Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching

Aug 09

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Apr 14

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 31

Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly

Dec 15

China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018

Sep 21

China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Sep 02

China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward

Jun 22

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064

Apr 14

China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around

Jan 16

These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely

Oct 11

China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year

Sep 15

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056

Sep 01

China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns

Aug 26

Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture

May 22

We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt

Apr 25

Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?

Mar 14

How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?

Feb 21

Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?

Feb 03

Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?

Jan 16

China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet

Dec 29

Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?

Dec 14

China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment

Nov 29

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Shanghai Pioneer Holding yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1345 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	1,648	164	55	124	N/A
3/31/2024	1,607	155	-54	2	N/A
12/31/2023	1,567	146	-163	-119	N/A
9/30/2023	1,600	168	-180	-128	N/A
6/30/2023	1,634	190	-198	-137	N/A
3/31/2023	1,595	213	-89	-22	N/A
12/31/2022	1,556	235	19	93	N/A
9/30/2022	1,482	216	134	194	N/A
6/30/2022	1,408	196	250	296	N/A
3/31/2022	1,422	169	236	269	N/A
12/31/2021	1,435	143	222	242	N/A
9/30/2021	1,415	117	194	244	N/A
6/30/2021	1,395	91	166	246	N/A
3/31/2021	1,364	72	81	160	N/A
12/31/2020	1,332	52	-4	74	N/A
9/30/2020	1,325	45	-9	38	N/A
6/30/2020	1,318	37	-15	2	N/A
3/31/2020	1,317	71	128	141	N/A
12/31/2019	1,316	105	272	281	N/A
9/30/2019	1,304	84	240	246	N/A
6/30/2019	1,293	63	208	212	N/A
3/31/2019	1,459	74	168	170	N/A
12/31/2018	1,624	85	128	129	N/A
9/30/2018	1,851	171	135	141	N/A
6/30/2018	2,077	258	142	153	N/A
3/31/2018	2,116	269	N/A	193	N/A
12/31/2017	2,154	279	N/A	234	N/A
9/30/2017	2,083	279	N/A	297	N/A
6/30/2017	2,012	280	N/A	361	N/A
3/31/2017	1,901	259	N/A	352	N/A
12/31/2016	1,790	237	N/A	342	N/A
9/30/2016	1,627	174	N/A	317	N/A
6/30/2016	1,464	111	N/A	292	N/A
3/31/2016	1,462	143	N/A	298	N/A
12/31/2015	1,461	174	N/A	305	N/A
9/30/2015	1,533	231	N/A	192	N/A
6/30/2015	1,605	287	N/A	79	N/A
3/31/2015	1,573	274	N/A	31	N/A
12/31/2014	1,540	262	N/A	-18	N/A
9/30/2014	1,500	262	N/A	-50	N/A
6/30/2014	1,460	263	N/A	-82	N/A
3/31/2014	1,366	250	N/A	-17	N/A
12/31/2013	1,272	238	N/A	48	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1345 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.3% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: 1345 'un kazançlarının Hong Kong pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: 1345 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: 1345 şirketinin gelirinin Hong Kong pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: 1345 şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1345 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Shanghai Pioneer Holding Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Shanghai Pioneer Holding Ltd Provides Earnings Guidance for the Year Ended 31 December 2022

China Pioneer Pharma Holdings Limited Provides Financial Guidance for the Year Ended 31 December 2020

Recent updates

Upcoming dividend of HK$0.048 per share

First half 2024 earnings released: EPS: CN¥0.081 (vs CN¥0.065 in 1H 2023)

Shanghai Pioneer Holding Ltd Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2024, Payable on 15 November 2024

Shanghai Pioneer Holding Ltd to Report First Half, 2024 Results on Aug 28, 2024

Shareholders Should Be Pleased With Shanghai Pioneer Holding Ltd's (HKG:1345) Price

Upcoming dividend of HK$0.024 per share

Full year 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.20 in FY 2022)

Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024

Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024

Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings

Investor sentiment improves as stock rises 21%

Final dividend of HK$0.024 announced

Shanghai Pioneer Holding Ltd, Annual General Meeting, May 24, 2024

Full year 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.20 in FY 2022)

Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks

Shanghai Pioneer Holding Ltd to Report Fiscal Year 2023 Results on Mar 25, 2024

Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital

Now 23% overvalued

New minor risk - Share price stability

Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?

Less than half of directors are independent

Shanghai Pioneer Holding Ltd Announces Board Changes

New major risk - Earnings quality

Upcoming dividend of HK$0.024 per share at 3.0% yield

Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024

Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024

First half 2023 earnings released: EPS: CN¥0.065 (vs CN¥0.10 in 1H 2022)

Shanghai Pioneer Holding Ltd Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on October 20, 2023

Shanghai Pioneer Holding Ltd to Report First Half, 2023 Results on Aug 29, 2023

Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of HK$0.048 per share at 2.4% yield

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Investor sentiment improves as stock rises 23%

Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

Full year 2022 earnings released

Shanghai Pioneer Holding Ltd Provides Earnings Guidance for the Year Ended 31 December 2022

Shanghai Pioneer Holding Ltd to Report Fiscal Year 2022 Results on Mar 27, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly

Less than half of directors are independent

Upcoming dividend of HK$0.018 per share

China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018

China Pioneer Pharma Holdings Limited Announces Management Changes

Investor sentiment improved over the past week

China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year

First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.057 in 1H 2021)

China Pioneer Pharma Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 20 October 2022

China Pioneer Pharma Holdings Limited to Report First Half, 2022 Results on Aug 31, 2022

Investor sentiment improved over the past week

China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward

Upcoming dividend of HK$0.064 per share

Less than half of directors are independent

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064

China Pioneer Pharma Holdings Limited, Annual General Meeting, May 18, 2022

Full year 2021 earnings released: EPS: CN¥0.12 (vs CN¥0.043 in FY 2020)

China Pioneer Pharma Holdings Limited Announces Dividend for the Year Ended 31 December 2021, Payable on 10 June 2022

Investor sentiment improved over the past week

China Pioneer Pharma Holdings Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Investor sentiment improved over the past week

China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around

Executive Chairman recently sold HK$17m worth of stock

Investor sentiment improved over the past week

These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely

China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year

China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.025 in 1H 2020)

China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture